Dry Age Related Macular Degeneration (dAMD) and geographic atrophy represent 85% of AMD, with no approved therapeutic options besides experimental cell therapy. To offer a new way to tackle this problem, Phenocell has developed unique phenotypic assays with retinal cells derived from iPSC. This webinar will explain how this assay platform can dramatically increase the relevance of tested molecules.

To register : https://phenocell.com/dry-amd-webinar-registration